Inducible myocardial ischaemia is considered to be a prerequisite for the clinical benefit of coronary revascularisation [1] . In this regard, the introduction of invasive pressure-derived physiological indices to guide myocardial revascularisation represented a major breakthrough in the treatment of patients with coro-
Summary
The use of coronary physiology to guide myocardial revascularisation was shown to improve clinical outcomes and reduce costs in patients with coronary artery disease. Fractional flow reserve (FFR) is the most commonly used pressure-derived physiological index for coronary lesion assessment, being supported by a body of compelling randomised evidence, but its uptake into clinical practice remains unacceptably low.
The instantaneous wave-free ratio (iFR) is a novel adenosine-free pressurederived index of coronary stenosis severity that was recently introduced to circumvent the limitations of existing hyperaemic pressure-derived indices with the aim of increasing the widespread adoption of coronary physiology assessment. Following the recent publication of two large-scale, randomised, patient outcome clinical trials, iFR has emerged as a simpler, safe and effective alternative to FFR to guide coronary revascularisation. This has led to renewed interest in the field of coronary physiology and challenges current paradigms supporting the need for pharmacologically-induced maximal hyperaemia as an essential requirement for coronary stenosis assessment.
This review aims at addressing the physiological concepts and patient outcome evidence supporting the use of iFR and discuss the recent development of novel iFR-based applications allowing full integration of invasive coronary physiology in percutaneous coronary intervention planning strategy. 
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nary artery disease (CAD), by moving the focus of coronary revascularisation from anatomy to physiology [2] (table 1). The main premise of coronary physiology assessment is to determine the functional significance of individual stenoses at the time of clinical decisionmaking, providing an objective marker to identify ischaemic lesions, and therefore patients, most likely to benefit from coronary revascularisation [1] .
Fractional flow reserve (FFR) is the most widely used pressure-derived invasive physiological index for coronary lesion assessment in contemporary clinical practice. FFR is the ratio of the mean distal coronary pressure (Pd) to the mean proximal coronary pressure (Pa) across a stenosis during maximal hyperaemia, a condition that is commonly achieved by the intracoronary or intravenous administration of a potent vasodilator agent, such as adenosine [3] [4] [5] . Based on the results of landmark clinical trials [6] [7] [8] [9] [10] [11] (table 2) , most recent guidelines recommend the use of FFR to identify haemodynamically significant coronary lesions in patients with stable CAD [1, 12] . Despite this, the worldwide adoption of FFR into current clinical practice remains limited [13] , accounting for less than 10% of coronary procedures in Switzerland [14] . Potential reasons for the low uptake of coronary physiology assessment include technical challenges related to FFR measurements, time consumption, inadequate or lack of reimbursement, physician preferences, patient-related discomfort, and contraindications to or costs as- ACS: acute coronary syndrome; CAD: coronary artery disease; FFR: fractional flow reserve; MACE: major adverse cardiac events; OMT: optimal medical treatment; PCI: percutaneous coronary intervention. 1 Composite of all-cause mortality, myocardial infarction, CABG, coronary angioplasty, and any procedure-related complication necessitating major intervention or prolonged hospital stay. 2 Composite of death, myocardial infarction, and any repeat revascularisation. 3 Composite of death from any cause, non-fatal myocardial infarction, or unplanned hospitalisation leading to urgent revascularisation. 
Fractional flow reserve
FFR is currently considered the gold standard for assessment of the functional significance of coronary stenosis, being supported by a large body of randomised evidence demonstrating its value in clinical decision making [6] [7] [8] [9] [10] [11] . FFR is defined as the ratio of maximum achievable coronary blood flow (CBF) in the presence of an epicardial coronary stenosis and the theoretical maximum CBF in the hypothetical absence of the coronary stenosis during maximal pharmacological vasodilation [3] .
Patient outcome trials
The use of FFR to guide coronary revascularisation is supported by several randomised patient outcome trials (table 2) . DEFER (Deferral versus performance of percutaneous transluminal coronary angioplasty (PTCA) in patients without documented ischaemia) was a prospective, randomised trial including 325 patients with stable CAD referred for elective percutaneous coronary intervention (PCI) who underwent FFR assessment of de novo intermediate coronary lesions [6] . Patients with FFR ≥0.75 were randomly assigned to deferral or PCI, whereas patients with FFR <0.75 underwent PCI as planned (reference group). The primary endpoint was the absence of major adverse cardiac events (MACE) during 24 months of follow-up. Eventfree survival was similar between deferred and treated patients (89 vs 83% at 24 months), but was significantly lower in the reference group (78% at 24 months) [6] .
Moreover, the proportion of patients free from angina was similar in deferral and PCI groups (70 vs 51%) but was significantly higher in the reference group (80%) [6] . Subsequently, 5-year follow-up of the DEFER cohort confirmed that long-term outcomes of patients after deferral of PCI in intermediate coronary stenosis with FFR ≥0.75 were excellent [7] .
FAME (Fractional Flow Reserve versus Angiography for
Multivessel Evaluation) was a prospective, multicentre trial that randomly assigned 1005 patients with multivessel CAD to FFR-guided or to angiography aloneguided coronary revascularisation with drug-eluting stents [8] . The incidence of the primary endpoint of MACE, a composite of death, nonfatal myocardial infarction (MI) or repeat revascularisation at 1 year, was significantly lower in the FFR group compared with the angiography-alone group (13.2 vs 18.3%, respectively; relative risk 0.72, 95% confidence interval [CI] 0.54-0.96; p = 0.02) [8] . Furthermore, physiology-guided revascularisation using a FFR threshold >0.80 was associated with fewer stents, less contrast volume, and reduced costs compared with coronary revascularisation guided by visual assessment only.
In the prospective, multicentre, randomised FAME 2 trial, patients with angiographically documented stable CAD and candidates for PCI underwent FFR assessment to determine the haemodynamic severity of each indicated coronary stenosis [9] . Patients with an FFR ≤0.80 in at least one stenosis were randomly assigned to an FFRguided PCI strategy plus optimal medical therapy (OMT) or OMT alone, whereas patients with an FFR >0.80 in all vessels with indicated coronary stenoses were enrolled in a registry and received OMT. The primary endpoint was a composite of death, MI, or unplanned hospitalisation leading to urgent revascularisation during the first 2 years. Recruitment was halted prematurely after enrolment of 1220 patients (median follow-up 7 months) owing to a large reduction in the primary composite endpoint in the FFR-guided PCI+OMT group compared with the OMT alone group (4.3 vs 12.7%, respectively; hazard ratio [HR] 0.32, 95% CI 0.19-0.53; p <0.001), driven by significantly lower rates of urgent revascularisation (1.6 vs 11.1%; HR 0.13, 95% CI 0.06-0.30; p <0.001) in the FFR-guided PCI arm. Notably, rates of death from any cause, cardiac death and MI were not statistically different between the two groups [9] . The longer-term followup of the FAME 2 trial demonstrated persistent lower rates of the primary composite endpoint in the FFRguided PCI group, primarily as a result of lower rates of urgent revascularisation in the FFR-guided PCI arm, with no significant between-group differences in the rates of all-cause death, cardiac death, or MI, at 2- [10] and 3-year [11] follow-up.
Based on the results of these landmark studies, current 
Limitations of the hyperaemic pressure-derived physiological indices
The concept of FFR and hyperaemic pressure-derived indices of coronary stenosis severity depends on the fundamental physiological principle that coronary pressure is directly proportional to CBF when microvascular resistance is stable, a condition that is commonly achieved during the administration of hyperaemic agents, such as adenosine [3, 16] . Under these conditions, the decrease in pressure across a coronary stenosis reflects the decrease in CBF to the amount of subtended myocardium. This assumption was translated into the paradigm that coronary pressure can only be considered as a surrogate to CBF during maxi- With an FFR cut-off value of 0.80, an iFR <0.86 was associated with a high positive predictive value (92%) to confirm treatment, whereas an iFR >0.93 was associated with a high negative predictive value (91%) to defer treatment. Limiting the use of adenosine to cases with iFR values between 0.86 to 0.93 obviated the need for a vasodilator drug in 57% of patients (76% in the FFR 0.75-0.80 range), while maintaining 95% agreement with an FFR-only strategy [29] . However, with the recent publication of randomised patient outcome trials comparing iFR using a single cut-off value with FFR to guide coronary revascularisation, the routine use of an iFR-FFR hybrid strategy is currently not recommended. At 1-year follow-up, the primary endpoint occurred similarly in the iFR and FFR groups (6.7 vs 6.1%, respectively; difference in risk 0.7%; 95% CI -1.5-2.8; p = 0.007 for noninferiority). There were no significant betweengroup differences in the risk of each component of the composite endpoint. The study results were consistent within major subgroups, and the rates of ischaemic endpoints, including MI, target-lesion revascularisation, in-stent restenosis and stent thrombosis, did not differ significantly between the two groups. Similarly to DEFINE-FLAIR, a significantly higher proportion of patients in the FFR group than in the iFR group reported chest discomfort during the procedure (68.3 vs 3.0%, respectively; p <0.001). Furthermore, the total number of lesions assessed was significantly greater in the iFR group than in the FFR group, which was possibly related to the fact that operators using FFR are unlikely to persist with additional lesion assessment in patients experiencing adenosine-related chest discomfort. These findings tend to support the central notion that iFR is a much more tolerable procedure and therefore permits an easier and a more complete assessment of coronary anatomy.
Instantaneous wave-free ratio

Patient outcome trials
Pooled patient-level meta-analysis of DEFINE-FLAIR and iFR-SWEDEHEART
The pooled patient-level meta-analysis of DEFINE- Physiology-guided deferral of coronary revascularisation occurred more frequently in the pooled iFR group than in the pooled FFR group (50.0 vs 45.0%, respec- 
Limitations of the iFR concept
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Introduction
Heart failure with preserved ejection fraction (HFpEF)
is a frequent disease with a prevalence of 1.1-5.5% in the general population in Europe [1] . From a pathophysiological point of view, symptoms and a prognosis may depend on lack of stroke volume reserve and/or elevated pulmonary artery pressure [2, 3] . In fact, it was
shown that left atrial pressure as a major determinant of pulmonary venous and pulmonary artery pressure correlates with symptoms and prognosis [4] . Accordingly, reduction of left atrial pressure may be a promising therapeutic strategy. Consequently, devices have been developed to reduce left atrial pressure through creation of a shunt between the left and right atria [5, 6] . Exercise haemodynamic measurements before device implantation showed significant rises in PCWP from 17 ± 5 to 35 ± 8 mm Hg, and in RA from 9 ± 4 to 11 ± 5 mm Hg from rest to peak exercise. The shunt driving pressure (PCWP−CVP) increased from rest to exercise from 8 ± 4 to 17 ± 8 mm Hg. The mean exercise time before device implantation was 7.3 ± 3.1 min at a work load of 43 ± 18 W.
Exercise time increased to 8.2 min ± 3.4 (p = 0.0275) and
work load increased to 49 ± 20 W at 6 months after IASD implantation. These favourable changes were associated with a reduction of peak exercise PCWP from 34 ± 8 to 32 
Discussion
The studies show that the IASD is safe, reduces PCWP with previous work indicating that pulmonary artery pressure is of key pathophysiological relevance in patients with HFpEF [9] . Moreover, there is considerable evidence that pulmonary artery pressures are predictors of mortality in these patients [4, 10] .
Pulmonary artery pressure can be reduced by vasodilators and diuretics, and it has been shown that medical therapy guided by pressure monitoring reduces heart failure hospitalisation, whereas no other therapeutic approach (with the exception of exercise training) has yet shown to be effective in this group of patients [9] . These data, together with the available date from the IASD creates much enthusiasm that reducing pulmonary artery pressure by a persistent shunt may be a new therapeutic option in patients with HFpEF and HFmrEF, and perhaps also in HFrEF.
The IASD approach critically depends on the left to right pressure gradient to drive the shunt and the size of the hole in the atrial septum. As an inclusion criterion in the IASD studies, PCWP had to be above Finally, the haemodynamic findings support previous recommendations that HFpEF (or HFmrEF) may require haemodynamic testing during exercise [2, 11] . In all IASD-studies, 30% of patients would not have met the inclusion criteria at rest, but showed clearly elevated pulmonary artery pressures during exercise.
In conclusion, reducing pulmonary artery pressure with the IASD may be a new therapeutic option to treat symptomatic HFpEF and HFmrEF patients.
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New compounds for the treatment of pulmonary hypertension
Treatment of pulmonary arterial hypertension
Treatment of pulmonary hypertension is a three-step strategy starting with general measures, which is followed by supportive drug therapy and specific pharmacological treatment [2] .
General measures are physical activity, birth control and post-menopausal hormonal therapy, infection prevention, psychosocial support, adherence to treatment, genetic counselling and counselling about travel. Only the specific pharmacological treatment of PAH is discussed here, because supportive drug treatment is extensively reviewed elsewhere [3] [4] [5] [6] [7] [8] .
Endothelin receptor antagonists
The 
Sildenafil, tadalafil
The first orally active, potent and selective PDE-5i, silde- 
Riociguat
The sGC activator riociguat (Adempas®), the first molecule of its class, is approved for the treatment of pa- (table 1) .
Prostacyclin analogues and prostacyclin receptor agonists
Future compounds
The last years have seen the testing of drugs such as imatinib mesylate (Glivec®), which inhibits plateletderived growth factor signalling. The IMPRES study investigated imatinib mesylate as add-on treatment in PAH patients in WHO class III or IV in spite of specific therapy. In the treatment group, exercise capacity and haemodynamics improved significantly (6-minute walking test +32 meters, PVR -397 dynes*sec -1 *cm -5 ; respectively). However, functional class, time to clinical 
Combination therapy
Most 
Conclusion
The emergence of specific treatments for PAH has improved functional status, exercise capacity and time to clinical worsening over the last two decades. The recently developed compounds macitentan, riociguat, and selexipag provide additional benefit when given either as monotherapy or in combination with compounds interacting with other pathways active in PAH.
The absence of an effect on PAH-associated mortality remains a drop of bitterness. However, a post-hoc analysis of the SERAPHIN study showed that the incidence of a morbidity events <3 months after study inclusion was associated with increased mortality [42], suggesting that reduced morbidity may be associated with improved prognosis.
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Extension from the right atrium through the aortic valve via entrapment in a patent foramen ovale He was treated initially with a heparin infusion for 5 days, then transitioned to apixaban. He remained stable during a 7-day hospital stay. He was seen in clinic 3 months after discharge and has done well with no noted complaints or signs of embolism. 
Discussion
Evidence from autopsy reports suggest up to 35% of the population may possess a PFO [1] . We describe a case of an elderly gentleman with a DVT, bilateral pulmonary emboli and a large thrombus extending from the right atrium through the aortic valve via a PFO. There is no guideline or expert consensus on the best way to treat such a condition. A literature review of reported cases of thrombus entrapped in a PFO suggested either surgery or anticoagulation as treatment [2, 3] . Surgery was the more popular option, and anticoagulation was preferred in cases where surgery was considered high risk [2, 3] . Anticoagulation has been effective for our patient to date. Owing to the paucity of available data, longterm treatment for a thrombus entrapped in a PFO is unknown. The risk of a future embolus across the PFO and benefit of closure with this type of presentation are also unknown. Further research is necessary to answer these questions. 
Annual Congress of the Swiss Society of Cardiology
The Amgen research prize
The Amgen research prize, formerly the cardiovascular biology prize supported by Werner Lambert, then Pfizer and now Amgen, was founded by Prof. Thomas F. Lüscher in 1997 and was first awarded a year later at the annual congress of the Swiss Society of Cardiol- ogy to a promising young cardiovascular researcher. The prize consisted then, as it does now, of 30 000 CHF for future research by the winner. Furthermore, winners are asked to provide a review article on their research for Cardiovascular Medicine to make the work known at the national level. From the beginning, it was of importance to the founder to ensure a fair and objective assessment of the applications. To that end, a scientific board, consisting not only of Swiss members, but also experts from abroad was assembled to minimise conflicts of interest. Furthermore, the president himself never participated in the rating, but rather assured proper procedures for selection of the winner. 
NEWS 202
The general assembly
The general assembly of the Swiss Society of Cardiology took place on Wednesday June 6 and was chaired elegantly by the outgoing president Michael Zellweger from Basel, who has effectively led the society for the last 2 years ( fig. 6 ). He will be followed by the incoming president for the next 2-year term, Giovanni Pedrazzini from Lugano. Michael Billinger was elected as the new representative of Bern University to follow Thomas Suter, who stepped down, and Christoph Wyss from the Heart Clinic Hirslanden, who will take over the role of Urs Kaufman (who played a pivotal role in the negotiations on reimbursement for cardiological clinical services). His commitment to these important issues was highly appreciated by the assembly with an impressive round of applause. Finally, Patrick Monnier, a representative of the practicing cardiologists, was replaced by Tomoé Stampfli Andres from the Hospital La Tour in Meyrin. Lastly, Felix Tanner from Zurich was elected vice-president and, as such, president-elect for the next term 2020 to 2022. After the report of the president, Paul Erne form Lucerne and Peter Buser from Basel were named honorary members of the Swiss Society of Cardiology ( fig. 7) . The president reminded the members that the Swiss Society of Cardiology celebrated its 70th birthday this year at their annual congressan impressive tradition for a scientific society and good reason to look back on developments in cardiology and cardiac surgery, as wel as to look forward, to speculate and to dream about future advancements. This was indeed the special focus of the 2018 programme, with eminent keynote speakers in different areas of the field highlighting the advances in cardiology, and those that Switzerland, in particular, could enjoy. Future developments were also discussed. Thus, as the president mentioned, cardiology lives up to the statement of Jack Nickolson that "aging means getting better!" Important items were the changes in reimbursement for cardiology services in Switzerland and the political issues behind them, which will make life more difficult for practising colleagues. Furthermore, the proposal of the board to create subspeciality certifications attracted an unforeseen number of members of the Swiss Society of Cardiology to the general assembly. The president explained in detail the process the board followed to come up with the proposal, which lasted al- most two years. The proposal had been send to all members of the Swiss Society of Cardiology beforehand to allow for an informed decision making and eventually vote. Many cardiology societies worldwide have introduced such a concept and a matching curriculum that reflects the impressive developments in this speciality in the last three decades. For invasive procedures such as percutaneous coronary angioplasty, transcatheter aortic valve implantation and the ablation of arrhythmias in particular, a comprehensive training programme is required today to ensure efficacy and safety for patients undergo- ing such procedures. In spite of this, the proposal of the board was surprisingly rejected with 110 voting no against 69 yes and 2 abstentions.
The future
Overall, this year's annual congress of the Swiss Society of Cardiology was a true success. Its members can truly be proud of it, but life goes on and we already have to think about the next annual meeting which will take place in Interlaken on June 18-21 in 2019. Some issues remain, however, in particular the question of whether we should still allow cardiologists with only a basic training and certified as FHM of cardiology to perform any investigation or procedure without documentation of successfully passing a structured practical and theoretical core curriculum and examination. History will tell, and we shall learn that those who do not listen to the historical process -as Mikhal Gorbatchov put itwill be overruled. We shall see -as always predictions are difficult, but this issue will not disappear with the 2018 vote. Indeed it is likely come back on the A distinguished international teaching faculty will contribute to an outstanding programme on the latest scientific and therapeutic developments, as well as on new intervention and treatment strategies in cardiology. Special emphasis is being placed on the presentation and clinical implementation of review and disseminate the latest knowledge about advances in prevention, diagnosis and treatment of cardiovascular disease. Cardiology Update is designed for clinicians specialised in cardiology, but is also worthwhile for internal and general medicine specialists with an interest in cardiovascular disease. The main features of the course are state-of-the art lectures, interactive case presentations and clinical decision seminars. In addition, video live cases, "Meet the Expert" sessions, and poster sessions further complement the programme. In order to foster participation of young cardiologists, a dedicated session designed by SCOT, Swiss Cardiologists of Tomorrow, will be organised. The spirit of the course is a stimulating working and learning environment, combined with many opportunities for networking among faculty members and participants. Olivier Muller is the author of more than 130 publications in peer-reviewed, high impact factor journals and is currently involved in several trials related to the treatment of coronary artery disease, with a focus on myocardial infarction and coronary artery physiology. He is currently member of the Swiss working group for interventional cardiology. During the past 10 years, Olivier Muller has substantially contributed to improving education in the field of management of complications during coronary intervention. He is co-course director of the "Endovascular cardiac complication (ECC)" Lausanne Meeting and is highly involved in the PCRonline educational platform dedicated to management of complications during coronary intervention. 
